1375544-48-1Relevant articles and documents
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)
Curtin, Michael L.,Heyman, H. Robin,Clark, Richard F.,Sorensen, Bryan K.,Doherty, George A.,Hansen, T. Matthew,Frey, Robin R.,Sarris, Kathy A.,Aguirre, Ana L.,Shrestha, Anurupa,Tu, Noah,Woller, Kevin,Pliushchev, Marina A.,Sweis, Ramzi F.,Cheng, Min,Wilsbacher, Julie L.,Kovar, Peter J.,Guo, Jun,Cheng, Dong,Longenecker, Kenton L.,Raich, Diana,Korepanova, Alla V.,Soni, Nirupama B.,Algire, Mikkel A.,Richardson, Paul L.,Marin, Violeta L.,Badagnani, Ilaria,Vasudevan, Anil,Buchanan, F. Greg,Maag, David,Chiang, Gary G.,Tse, Chris,Michaelides, Michael R.
, p. 3317 - 3325 (2017/07/07)
Herein we disclose SAR studies that led to a series of isoindoline ureas which we recently reported were first-in-class, non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. Modification of the isoindoline and/or the terminal functiona
NAMPT AND ROCK INHIBITORS
-
Page/Page column 265-266; 274, (2012/05/21)
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the co